secwatch.observer — SEC 8-K summary
======================================

Issuer:     Emmaus Life Sciences, Inc. (EMMA)
CIK:        0000822370
Form:       8-K
Filed at:   2025-08-14T23:59:59+00:00
Accession:  0001213900-25-076672
Event type: earnings
Sentiment:  negative
Materiality: 0.60
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Emmaus Life Sciences Q2 net revenue down 48% to $2.8M; net loss narrows to $1.1M
--------------------------------------------------------------------------------

- Net revenue $2.8M, down 48% YoY from $5.4M; competition from generic L-Glutamine cited.
- Loss from operations $0.4M vs income of $0.6M in prior year.
- Net loss $1.1M ($0.02/share) vs $2.2M ($0.03/share) in Q2 2024; decrease due to lower other expense.
- Cash balance $0.9M at June 30, 2025, down from $1.4M at year-end 2024.
- Operating expenses reduced 33% to $3.0M, primarily from headcount reduction in Q4 2024.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/822370/000121390025076672/0001213900-25-076672-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/822370/000121390025076672/ea0253040-8k_emmaus.htm
  HTML page:      https://secwatch.observer/filing/0001213900-25-076672

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer